Solventum Corporation (SOLV) Stock Forecast & Price Target

Solventum is attractive because its simplified portfolio, with MedSurg now about 64% of revenue and Dental and Health Information Systems each near 18%, concentrates value in businesses with clear penetration and mix-up opportunities. Management’s framework points to 4%-5% organic growth, margin expansion from roughly 20.4% toward 23%-25%, and meaningful free-cash-flow improvement as separation-related costs roll off and the HIS separation is executed with a bias toward maximizing shareholder value. The business has already shown strong execution, with 2Q26 revenue of $2.209B, 9.5% organic growth, and adj. EPS of $2.55, while underpenetrated areas like NPWT, antimicrobial securement, and dental innovation can support further upside.

Solventum is facing a structurally cautious outlook because its growth engine remains uneven, with medsurg at about 64% of revenue while dental solutions and health information systems each contribute only 18%, leaving performance heavily dependent on a few areas. Downside risk centers on slower organic growth in key segments, weaker-than-expected margin expansion, higher interest expense from elevated rates, and intensified competition, while any negative update on the HIS separation could further pressure sentiment. Although FY26 guidance improved to 2.5%–3.0% organic growth, $7.10–$7.20 adjusted EPS, and 22.2%–22.7% adjusted operating margins, FY25 FCF was essentially flat and separation costs, ERP cut-over spending, and roughly 200 TSAs keep cash conversion and execution risk elevated.